Vir Biotechnology, Inc. (NASDAQ:VIR – Get Rating) insider Phillip Pang sold 4,991 shares of the business’s stock in a transaction that occurred on Tuesday, June 21st. The stock was sold at an average price of $24.89, for a total value of $124,225.99. Following the completion of the transaction, the insider now directly owns 144,000 shares in the company, valued at $3,584,160. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
NASDAQ:VIR opened at $24.54 on Thursday. The stock’s fifty day moving average is $23.22 and its 200 day moving average is $29.05. Vir Biotechnology, Inc. has a fifty-two week low of $18.21 and a fifty-two week high of $58.00. The firm has a market capitalization of $3.25 billion, a PE ratio of 2.71, a PEG ratio of 1.03 and a beta of -0.58.
Vir Biotechnology (NASDAQ:VIR – Get Rating) last released its quarterly earnings results on Thursday, May 5th. The company reported $3.85 earnings per share for the quarter, beating the consensus estimate of $3.21 by $0.64. Vir Biotechnology had a return on equity of 96.39% and a net margin of 52.29%. The company had revenue of $1.20 billion for the quarter, compared to analyst estimates of $811.05 million. During the same quarter in the prior year, the firm posted ($1.32) EPS. Vir Biotechnology’s quarterly revenue was up 59900.0% compared to the same quarter last year. As a group, analysts anticipate that Vir Biotechnology, Inc. will post 2.16 earnings per share for the current fiscal year.
Several brokerages have recently issued reports on VIR. TheStreet cut Vir Biotechnology from a “c-” rating to a “d+” rating in a report on Monday, March 28th. Needham & Company LLC decreased their price objective on Vir Biotechnology from $80.00 to $45.00 and set a “buy” rating on the stock in a report on Monday, March 28th. Robert W. Baird raised Vir Biotechnology from an “underperform” rating to a “neutral” rating and decreased their price objective for the stock from $36.00 to $28.00 in a report on Thursday, March 3rd. Finally, HC Wainwright decreased their price objective on Vir Biotechnology from $250.00 to $125.00 in a report on Thursday, May 12th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $61.33.
About Vir Biotechnology (Get Rating)
Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.
- Get a free copy of the StockNews.com research report on Vir Biotechnology (VIR)
- Victoria’s Secret Stock is Out of the Box
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.